The immunotherapy targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PD-1) has recently been demonstrated to be an effective approach to activate immune response and treat a wide range of cancers [1]. Here, PDCD1 is linked to cancer.